In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Interpace Diagnostics Group Inc (NASDAQ: IDXG), with a price target of $3. The company’s shares closed yesterday at $1.28.
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.3% and a 29.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Interpace Diagnostics Group Inc is a Moderate Buy with an average price target of $3.50.
See today’s analyst top recommended stocks >>
Based on Interpace Diagnostics Group Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $1.92 million. In comparison, last year the company had a GAAP net loss of $3.32 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Interpace Diagnostics Group, Inc. is an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.
